Cost Effectiveness Analysis In CER: Perhaps Not So Controversial After All?
Recent examination of cost effectiveness analyses conducted as part of comparative effectiveness research reveals that CEA and CER were in agreement about 70% of the time.
You may also be interested in...
Sanofi’s recent reduction of the Zaltrap price after the Memorial Sloan-Kettering Cancer Center said it would not provide the drug to its advanced colorectal cancer patients due to its high cost relative to Avastin highlights the role cost and available clinical evidence will have as payers make value-based purchasing decisions.
The controversy surrounding the recent recommendations on mammogram screenings by the U.S. Preventive Services Task Force has the potential to be played out again amid the continued push for more comparative effectiveness research
Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.